Company Filing History:
Years Active: 2010-2025
Title: Hsin-Ta Hsieh: Innovator in Cancer Regulation
Introduction
Hsin-Ta Hsieh is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer regulation through his innovative work on binding proteins. With a total of 4 patents, Hsieh's research focuses on enhancing T cell stimulation and inhibiting cancer cell growth.
Latest Patents
Hsieh's latest patents include the development of PD-L1 and OX40 binding proteins for cancer regulation. These patents provide both monospecific and bispecific proteins that specifically bind to OX40 and/or PD-L1. The exemplary proteins are designed to release inhibition through PD-L1 while stimulating T cells through OX40. Additionally, the polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, these binding sites may be linked through an immunoglobulin constant region. The patents also include anti-OX40 and anti-PD-L1 antibodies.
Career Highlights
Hsin-Ta Hsieh has worked with notable institutions such as National Taiwan University and Ap Biosciences Inc. His work has been instrumental in advancing the understanding of cancer treatment and immunotherapy.
Collaborations
Hsieh has collaborated with esteemed colleagues, including Guo-Dung Su and Jhong-Jhe You. Their combined efforts have contributed to the innovative research in the field of cancer regulation.
Conclusion
Hsin-Ta Hsieh's contributions to cancer regulation through his innovative binding proteins highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer treatment and immunotherapy.